387 related articles for article (PubMed ID: 12796698)
1. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
Oades GM; Senaratne SG; Clarke IA; Kirby RS; Colston KW
J Urol; 2003 Jul; 170(1):246-52. PubMed ID: 12796698
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation.
Coxon JP; Oades GM; Kirby RS; Colston KW
BJU Int; 2004 Jul; 94(1):164-70. PubMed ID: 15217454
[TBL] [Abstract][Full Text] [Related]
3. Pamidronate inhibits antiapoptotic bcl-2 expression through inhibition of the mevalonate pathway in prostate cancer PC-3 cells.
Iguchi K; Tatsuda Y; Usui S; Hirano K
Eur J Pharmacol; 2010 Sep; 641(1):35-40. PubMed ID: 20519142
[TBL] [Abstract][Full Text] [Related]
4. A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. I: In vitro studies.
Li L; Zhu Z; Joshi B; Porter AT; Tang DG
Anticancer Res; 1999; 19(1A):51-60. PubMed ID: 10226524
[TBL] [Abstract][Full Text] [Related]
5. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
Jagdev SP; Coleman RE; Shipman CM; Rostami-H A; Croucher PI
Br J Cancer; 2001 Apr; 84(8):1126-34. PubMed ID: 11308265
[TBL] [Abstract][Full Text] [Related]
6. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
[TBL] [Abstract][Full Text] [Related]
7. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
Virtanen SS; Väänänen HK; Härkönen PL; Lakkakorpi PT
Cancer Res; 2002 May; 62(9):2708-14. PubMed ID: 11980672
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
Dunford JE; Rogers MJ; Ebetino FH; Phipps RJ; Coxon FP
J Bone Miner Res; 2006 May; 21(5):684-94. PubMed ID: 16734383
[TBL] [Abstract][Full Text] [Related]
9. Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells.
Tanaka T; Kawashima H; Ohnishi K; Matsumura K; Yoshimura R; Matsuyama M; Kuratsukuri K; Nakatani T
Anticancer Res; 2009 Apr; 29(4):1089-94. PubMed ID: 19414350
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.
Goffinet M; Thoulouzan M; Pradines A; Lajoie-Mazenc I; Weinbaum C; Faye JC; Séronie-Vivien S
BMC Cancer; 2006 Mar; 6():60. PubMed ID: 16539721
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
12. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells.
Dumon JC; Journé F; Kheddoumi N; Lagneaux L; Body JJ
Eur Urol; 2004 Apr; 45(4):521-8; discussion 528-9. PubMed ID: 15041119
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS
Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631
[TBL] [Abstract][Full Text] [Related]
14. The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro.
Mitrofan LM; Pelkonen J; Mönkkönen J
Bone; 2009 Dec; 45(6):1153-60. PubMed ID: 19699819
[TBL] [Abstract][Full Text] [Related]
15. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy.
Clyburn RD; Reid P; Evans CA; Lefley DV; Holen I
Cancer Chemother Pharmacol; 2010 Apr; 65(5):969-78. PubMed ID: 19730863
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates: preclinical review.
Green JR
Oncologist; 2004; 9 Suppl 4():3-13. PubMed ID: 15459425
[TBL] [Abstract][Full Text] [Related]
17. Nitroxide tempo, a small molecule, induces apoptosis in prostate carcinoma cells and suppresses tumor growth in athymic mice.
Suy S; Mitchell JB; Samuni A; Mueller S; Kasid U
Cancer; 2005 Mar; 103(6):1302-13. PubMed ID: 15685617
[TBL] [Abstract][Full Text] [Related]
18. Apigenin drives the production of reactive oxygen species and initiates a mitochondrial mediated cell death pathway in prostate epithelial cells.
Morrissey C; O'Neill A; Spengler B; Christoffel V; Fitzpatrick JM; Watson RW
Prostate; 2005 May; 63(2):131-42. PubMed ID: 15486995
[TBL] [Abstract][Full Text] [Related]
19. Apoptotic signaling in bufalin- and cinobufagin-treated androgen-dependent and -independent human prostate cancer cells.
Yu CH; Kan SF; Pu HF; Jea Chien E; Wang PS
Cancer Sci; 2008 Dec; 99(12):2467-76. PubMed ID: 19037992
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonate treatment inhibits the growth of prostate cancer cells.
Lee MV; Fong EM; Singer FR; Guenette RS
Cancer Res; 2001 Mar; 61(6):2602-8. PubMed ID: 11289137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
